Tradestie Institutional Equity Comparison Engine
XOMA vs AGEN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AGEN Overall Edge
AGEN Captures Institutional Edge (4โ0 Pillars ยท 3โ7 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Agenus Inc. (AGEN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, XOMA trades at 21.5x Forward P/E with -3.9% operating margin (-22.6% YoY revenue) versus AGEN at 3.7x Forward P/E and 38.9% operating margin (+4.1% YoY). In options structure, XOMA sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against AGEN sits in BREAKDOWN (11th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
AGEN
XOMA 21.5x vs AGEN 3.7x Fwd P/E
Growth & Margin Winner
AGEN
Op Margin -3.9% vs 38.9% ยท YoY -22.6% vs +4.1%
Momentum & Technical Winner
AGEN
1Y +44.0% vs +46.4% ยท 52W Pos 78% vs 48%
Options & Structure Winner
AGEN
UNCLASSIFIED (100th %ile IV) vs BREAKDOWN (11th %ile IV)
XOMA
NASDAQ
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap
$781.8M
1M Return
-3.81%
1Y Return
+43.98%
Forward P/E
21.5x
Unified AI Score
55.8 / 100
HOLD
Tech 40.0
Fund 52.0
Flow 50.0
Mom 64.0
AGEN
NASDAQ
Agenus Inc.
Biological Products, (No Disgnostic Substances)
$6.34
-5.79% 1D
Market Cap
$310.8M
1M Return
+4.97%
1Y Return
+46.42%
Forward P/E
3.7x
Unified AI Score
52.7 / 100
HOLD
Tech 44.0
Fund 55.0
Flow 66.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
XOMA +43.98%
AGEN +46.42%
Spread: +16.74 pp (AGEN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
XOMA TTM Op. Margin: -3.9%
AGEN TTM Op. Margin: 38.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XOMA vs AGEN. Trailing 12-month operating profitability (XOMA -3.9% vs AGEN 38.9%) and valuation multiples (XOMA 21.5x vs AGEN 3.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | XOMA | AGEN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $781.8M | $310.8M | Larger Scale | XOMA |
| Trailing P/E Ratio Valuation | 28.2x | 29.9x | Lower Multiple | XOMA |
| Forward P/E Ratio Valuation | 21.5x | 3.7x | Lower Multiple | AGEN |
| Revenue Growth (YoY) Growth | -22.6% | +4.1% | Higher Growth | AGEN |
| Operating Margin (TTM) Profitability | -3.9% | 38.9% | Higher Margin | AGEN |
| Net Profit Margin Profitability | 69.6% | 30.8% | Higher Margin | XOMA |
| Return on Equity (ROE) Capital Efficiency | 34.2% | -1278.8% | Higher ROE | XOMA |
| 52-Week Range Position Momentum | 78% ($22โ$45) | 48% ($3โ$10) | Stronger Trend | XOMA |
| Beta / 30D Volatility Risk Regime | 0.68ฮฒ ยท 37% Vol | 1.60ฮฒ ยท 76% Vol | Lower Realized Risk | XOMA |
| Unified Institutional Score Composite Signal | 55.8 / 100 (HOLD) | 52.7 / 100 (HOLD) | Higher Composite | XOMA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full XOMA vs AGEN Buy Guide
XOMA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
AGEN
BREAKDOWN
33d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
11th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither XOMA nor AGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.